Turning Point Brands, Inc. — Form 8-K
Filed September 21, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 52/100
What the filing says
David E. Glazek, Executive Chairman since at least 2014, was appointed CEO effective October 1, 2026, succeeding Graham Purdy who is stepping down for personal reasons unrelated to any disagreement. The company reaffirmed 2026 Modern Oral net sales guidance of $260–$270M but tightened EBITDA guidance to $70–$80M (from $70–$90M prior), citing delayed onshoring benefits and elevated freight costs.
Why this rating
Leadership transition by internal promotion; material guidance tightening (EBITDA midpoint down ~$10M, ~1.3% of market cap), but no operational shock or major M&A. Moderate event for a $1.3B company.
See more from September 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.